A Phase I/II , Open, Multicentre, Dose-escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumour Activity of LM-302 in Patients With CLDN18.2 Positive Advanced Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TPX 4589 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors LaNova Medicines Limited

Most Recent Events

04 Jun 2024 Results assessing safety analysis of LM-302 and efficacy data in gastric/GEJ cancer were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
16 Apr 2024 Status changed from recruiting to active, no longer recruiting.
11 Oct 2023 Planned number of patients changed from 128 to 206.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight